$SOLV earnings report

Reported sales decreased 7.0%; organic sales decreased 2.8%, reflecting the expected 630 basis point (bps) impact of prior quarter advance orders placed ahead of the planned ERP system cutover during the current quarter. AlphAI read Solventum's Third Quarter 2026 filing as mixed. 2 quarters are on record below.

Third Quarter 2026

AlphAI · Earnings readSOLV · Third Quarter 2026 · ended September 30, 2026

Reported sales decreased 7.0%; organic sales decreased 2.8%, reflecting the expected 630 basis point (bps) impact of prior quarter advance orders placed ahead of the planned ERP system cutover during the current quarter

→Mixed quarter

Third-quarter sales and adjusted EPS declined year over year, but results were ahead of the company’s expectations, all segments contributed, ERP cutovers were completed, and Solventum increased its full-year adjusted EPS guidance.

Revenue
$1.95B
(7.0) % y/y
Advanced Wound Care
$528M
8.9 % y/y
Gross margin · GAAP
54.5 %
EPS · non-GAAP
$1.45
(3.6) % y/y
Full-Year 2026 outlook
Organic sales growth toward the high end of +2.5% to +3.0% range (toward the high end of +3.5% to +4.0% excluding ~100 bps of SKU exit impact)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Q3 2026 total net salesGAAP$1.95B–(7.0) %
Q3 2026 organic sales growthnon-GAAP(2.8) %–(2.8) %
Q3 2026 net sales of productGAAP$1.43B––
Q3 2026 net sales of software and rentalsGAAP$518M––
Q3 2026 gross profitGAAP$1.06B––
Q3 2026 GAAP gross marginGAAP54.5 %––
Q3 2026 adjusted gross marginnon-GAAP57.1 %––
Q3 2026 selling, general and administrative expensesGAAP$813M–4.2 %
Q3 2026 research and development expensesGAAP$181M–(1.1) %
Q3 2026 operating incomeGAAP$68M––
Q3 2026 operating income marginGAAP3.5 %–(7,710) bps
Q3 2026 adjusted operating incomenon-GAAP$387M––
Q3 2026 adjusted operating income marginnon-GAAP19.9 %–(70) bps
Q3 2026 net income (loss)GAAP−$12M–(100.9) %
Q3 2026 diluted earnings per shareGAAP$(0.07)–(101.0) %
Q3 2026 adjusted diluted earnings per sharenon-GAAP$1.45–(3.6) %
Q3 2026 net cash provided by operating activitiesGAAP$177M–136.0 %
Q3 2026 free cash flownon-GAAP$97M–540.9 %
Nine months ended September 30, 2026 total net salesGAAP$6.17B–(2.6) %
Nine months ended September 30, 2026 organic sales growthnon-GAAP2.9 %–2.9 %
Nine months ended September 30, 2026 gross profitGAAP$3.44B––
Nine months ended September 30, 2026 GAAP gross marginGAAP55.9 %––
Nine months ended September 30, 2026 adjusted gross marginnon-GAAP57.9 %––
Nine months ended September 30, 2026 operating incomeGAAP$329M––
Nine months ended September 30, 2026 operating income marginGAAP5.3 %–(2,720) bps
Nine months ended September 30, 2026 adjusted operating incomenon-GAAP$1.41B––
Nine months ended September 30, 2026 adjusted operating income marginnon-GAAP22.8 %–210 bps
Nine months ended September 30, 2026 net incomeGAAP$93M–(93.8) %
Nine months ended September 30, 2026 diluted earnings per shareGAAP$0.54–(93.7) %
Nine months ended September 30, 2026 adjusted diluted earnings per sharenon-GAAP$5.48–20.9 %
Nine months ended September 30, 2026 net cash provided by operating activitiesGAAP$215M–(21.5) %
Nine months ended September 30, 2026 purchases of property, plant and equipmentGAAP−$247M––
Nine months ended September 30, 2026 free cash flownon-GAAP−$32M–23.8 %
Cash and cash equivalents as of September 30, 2026GAAP$451M––
Short-term borrowings and current portion of long-term debt as of September 30, 2026GAAP$507M––
Long-term debt as of September 30, 2026GAAP$4.56B––

Segments

SegmentRevenueq/qy/y
Advanced Wound CareOrganic growth was 1.5%; constant currency growth was 8.7%, including a 7.2% Other impact.$528M–8.9 %
Infection Prevention and Surgical SolutionsOrganic growth was (5.7)% and constant currency growth was (5.7)%.$683M–(5.3) %
MedSurgOrganic growth was (2.8)%; constant currency growth was 0.1%, including a 2.9% Other impact.$1.21B–0.4 %
Dental SolutionsOrganic growth was (7.4)% and constant currency growth was (7.4)%.$317M–(6.7) %
Health Information SystemsOrganic growth was 4.4%; constant currency growth was 3.2%, including a (1.2)% Other impact.$356M–3.3 %
All OtherOrganic growth was (15.5)% and constant currency growth was (15.5)%.$64M–(15.9) %

Full-Year 2026 outlook

  • RevenueOrganic sales growth toward the high end of +2.5% to +3.0% range (toward the high end of +3.5% to +4.0% excluding ~100 bps of SKU exit impact)
  • NoteAdjusted EPS range of $7.20 to $7.30
  • NoteFree cash flow in the range of $200 million to $300 million

Capital returns

  • Purchases of treasury stock of $(403) million for the nine months ended September 30, 2026.
  • Treasury stock, at cost, was $(403) million as of September 30, 2026.

What drove it

  • The 2.8% Q3 organic sales decline reflected the expected 630 bps reversal of Q2 2026 advance orders placed ahead of the planned ERP system cutover during Q3 2026.
  • GAAP and adjusted gross margin increased primarily due to portfolio optimization, mix benefits and savings programs, partially offset by inflation and tariffs.
  • Adjusted operating income margin declined primarily due to the expected impact of Q2 2026 advance orders placed ahead of the planned ERP system cutover during Q3 2026.
  • Solventum exited ~90% of 3M transition service agreements, and ERP system cutovers were complete.
  • Advanced Wound Care received FDA 510(k) clearance for the combined use of Restrata and V.A.C. Therapy.

Concerns

  • Reported Q3 sales decreased 7.0% and organic sales decreased 2.8%.
  • Dental Solutions organic sales declined (7.4)% and Infection Prevention and Surgical Solutions organic sales declined (5.7)%.
  • GAAP operating income margin decreased to 3.5% from 80.6%, primarily due to the prior-year gain on sale of the purification & filtration business and higher current-year restructuring costs.
  • GAAP selling, general and administrative expenses increased primarily due to higher operating expenses associated with restructuring.
  • Nine-month free cash flow was $(32) million despite Q3 free cash flow of $97 million.

What to watch

  • Full-year organic sales growth is expected toward the high end of the +2.5% to +3.0% range.
  • Full-year adjusted EPS guidance was increased to $7.20 to $7.30.
  • Full-year free cash flow guidance remains $200 million to $300 million.
  • Execution following the completed ERP system cutovers and continued exit from 3M transition service agreements.
  • Progress on the planned separation of the Health Information Systems business, which is referenced in acquisition and divestiture-related costs.

Balance sheet and cash flow

  • Cash and cash equivalents were $451 million as of September 30, 2026, compared with $878 million as of December 31, 2025.
  • Short-term borrowings and current portion of long-term debt were $507 million and long-term debt was $4,561 million as of September 30, 2026.
  • Nine-month net cash used in financing activities was $(401) million, including purchases of treasury stock of $(403) million.
  • Nine-month net decrease in cash and cash equivalents was $(428) million.
  • Q3 operating cash flow of $177 million and free cash flow of $97 million were ahead of expectations driven by IEEPA tariff refund.

Analysis

Solventum reported Q3 net sales of $1,949 million, down 7.0%, while organic sales declined 2.8%. The company attributed the organic decline to an expected 630 bps reversal of Q2 2026 advance orders placed before the Q3 ERP cutover. Growth was uneven across the portfolio: Advanced Wound Care revenue rose 8.9% and Health Information Systems rose 3.3%, while Infection Prevention and Surgical Solutions, Dental Solutions and All Other declined on a reported and organic basis.

Profitability showed an important divergence between GAAP and adjusted results. GAAP gross margin increased to 54.5% from 54.2%, while adjusted gross margin increased to 57.1% from 55.8%, supported by portfolio optimization, mix benefits and savings programs, partly offset by inflation and tariffs. GAAP operating income was $68 million and GAAP operating margin was 3.5%, compared with $1,690 million and 80.6% in the prior year, which included a gain on sale of the purification & filtration business. Adjusted operating income was $387 million and adjusted operating margin was 19.9%, down from 20.6%, primarily reflecting the ERP-related advance-order effect.

GAAP net income was a loss of $(12) million and diluted EPS was $(0.07), while adjusted diluted EPS was $1.45, down 3.6%. The reconciliation identifies $50 million of restructuring costs, $157 million of 3M spin-off and separation-related costs, and $16 million of acquisition and divestiture-related items in Q3. For the first nine months, adjusted diluted EPS increased 20.9% to $5.48, while GAAP results remained affected by the prior-year purification and filtration sale gain and current-year restructuring, separation, litigation and acquisition and divestiture-related costs.

Cash generation improved in the quarter, with operating cash flow of $177 million and free cash flow of $97 million, which the company said was ahead of expectations due to an IEEPA tariff refund. However, nine-month operating cash flow was $215 million versus $274 million and nine-month free cash flow was $(32) million. Cash and cash equivalents were $451 million at September 30, 2026, while short-term borrowings and current portion of long-term debt were $507 million and long-term debt was $4,561 million. The company also reported $(403) million of nine-month purchases of treasury stock.

Management raised adjusted EPS guidance to $7.20 to $7.30 from $7.10 to $7.20 and expects organic sales growth toward the high end of the +2.5% to +3.0% range. It affirmed free cash flow guidance of $200 million to $300 million. The guide and management commentary place emphasis on post-cutover sales normalization, continued margin expansion from portfolio, mix and savings initiatives, and cash-flow conversion in the remainder of the year.

Management, verbatim

Solventum delivered third quarter results ahead of our expectations, with every segment contributing, even as we completed our largest ERP cutover; we expect to be near the top end of our full-year organic sales growth range, and are raising our full-year adjusted earnings per share outlook.

Bryan Hanson, chief executive officer of Solventum

With separation now more than 90% complete and our growth drivers gaining momentum, we are well positioned to accelerate sales growth and expand margins. We have differentiated innovation, a strong pipeline of new products and a significant opportunity to expand penetration of our existing brands with customers we already serve.

Bryan Hanson, chief executive officer of Solventum

Not in the filing

stated, not guessed
  • Q3 cash, debt and treasury-share repurchase amounts were not reported as standalone quarterly figures.
  • Dividend amount was not reported.
  • Forward guidance for revenue in dollars, gross margin, operating expenses and tax rate was not reported.
  • Q3 and nine-month revenue and operating-income figures for Advanced Wound Care and Infection Prevention and Surgical Solutions were reported only as components of MedSurg; standalone operating income and operating margins for those subcategories were not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readSOLV · Second Quarter 2026 · ended June 30, 2026

Solventum Reports Second Quarter 2026 Financial Results

✓Strong quarter

Organic sales increased 9.5%, adjusted diluted earnings per share increased 50.9% to $2.55, and the company increased full-year guidance for organic sales growth, adjusted EPS and free cash flow.

Revenue
$2.21B
2.2% y/y
Advanced Wound Care
$537M
14.9% y/y
EPS · non-GAAP
$2.55
50.9% y/y

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net sales, three months ended June 30, 2026GAAP$2.21B–2.2%
Selling, general and administrative expenses, three months ended June 30, 2026GAAP$927M–20.1%
Research and development expenses, three months ended June 30, 2026GAAP$178M–(5.8)%
Operating income margin, three months ended June 30, 2026GAAP8.2%–(170) bps
Adjusted operating income margin, three months ended June 30, 2026non-GAAP28.4%–650 bps
Net income, three months ended June 30, 2026GAAP$92M–2.2%
Diluted earnings per share, three months ended June 30, 2026GAAP$0.53–3.9%
Adjusted diluted earnings per share, three months ended June 30, 2026non-GAAP$2.55–50.9%
Net cash provided by operating activities, three months ended June 30, 2026GAAP$227M–34.3%
Free cash flow, three months ended June 30, 2026non-GAAP$144M–144.1%
Net sales, six months ended June 30, 2026GAAP$4.22B–(0.4)%
Selling, general and administrative expenses, six months ended June 30, 2026GAAP$1.75B–13.8%
Research and development expenses, six months ended June 30, 2026GAAP$367M–(3.7)%
Operating income margin, six months ended June 30, 2026GAAP6.2%–(250) bps
Adjusted operating income margin, six months ended June 30, 2026non-GAAP24.2%–340 bps
Net income, six months ended June 30, 2026GAAP$105M–(53.7)%
Diluted earnings per share, six months ended June 30, 2026GAAP$0.60–(53.8)%
Adjusted diluted earnings per share, six months ended June 30, 2026non-GAAP$4.02–32.7%
Net cash provided by operating activities, six months ended June 30, 2026GAAP$38M–(80.8)%
Free cash flow, six months ended June 30, 2026non-GAAP−$129M–(514.3)%

Segments

SegmentRevenueq/qy/y
Advanced Wound CareOrganic growth was 7.1%; the company cited strong performance across all reportable segments, primarily driven by volume and product mix and including the expected benefit of advance orders placed ahead of ERP cutovers.$537M–14.9%
Infection Prevention and Surgical SolutionsOrganic growth was 10.1%; the company cited strong performance across all reportable segments, primarily driven by volume and product mix and including the expected benefit of advance orders placed ahead of ERP cutovers.$836M–11.3%
MedSurgOrganic growth was 8.9%; the company cited strong performance across all reportable segments, primarily driven by volume and product mix and including the expected benefit of advance orders placed ahead of ERP cutovers.$1.37B–12.7%
Dental SolutionsOrganic growth was 15.2%; the company cited strong performance across all reportable segments, primarily driven by volume and product mix and including the expected benefit of advance orders placed ahead of ERP cutovers.$396M–17.0%
Health Information SystemsOrganic growth was 5.4%; Solventum announced the intent to separate this business segment as part of the portfolio optimization phase of its transformation strategy.$354M–4.4%
All OtherOrganic growth was 10.6%. All Other includes the Drinking Water business and sales related to product supplied to 3M and other supply agreements related to legacy 3M business and assumed by the Company at Spin-Off.$87M–11.8%

Full-Year 2026 outlook

  • NoteOrganic sales growth: +2.5% to +3.0% (+3.5% to +4.0% excluding ~100 bps of SKU exit impact)
  • NoteAdjusted diluted EPS: $7.10 to $7.20
  • NoteFree cash flow: $200 million to $300 million

What drove it

  • Organic sales growth of +9.5% reflected strong performance across all reportable segments, primarily driven by volume and product mix.
  • Quarterly organic growth included the expected benefit of advance orders placed ahead of ERP cutovers.
  • GAAP and adjusted gross margin both increased, driven by IEEPA tariff refund.
  • Adjusted operating income margin increased primarily due to a combination of IEEPA tariff refund and ERP-timing benefit.
  • Quarterly operating cash flow and free cash flow were ahead of expectations, driven by timing of tax payments and insurance proceeds.
  • Solventum announced the intent to separate its Health Information Systems business segment.

Concerns

  • GAAP operating income margin decreased 170 bps to 8.2%, primarily driven by net legal costs, separation and restructuring costs.
  • GAAP selling, general and administrative expenses increased 20.1%, primarily due to higher costs associated with separation activities and net legal costs.
  • Six-month net income decreased 53.7% to $105 million and six-month diluted earnings per share decreased 53.8% to $0.60.
  • Six-month operating cash flow decreased 80.8% to $38 million and six-month free cash flow was $(129) million.
  • Quarterly organic sales growth included the expected benefit of advance orders placed ahead of ERP cutovers.
  • Full-year organic sales guidance includes an approximately 100 bps impact from SKU exits.

What to watch

  • Execution and timing of the proposed separation of the Health Information Systems business segment.
  • The durability of organic sales growth after the expected benefit of advance orders placed ahead of ERP cutovers.
  • The effect of SKU exits on full-year organic sales growth.
  • Whether the IEEPA tariff refund and ERP-timing benefit continue to support adjusted operating income margin.
  • Conversion of quarterly cash-flow strength into the full-year free-cash-flow guidance range of $200 million to $300 million.

Balance sheet and cash flow

  • Operating cash flow of $227 million; free cash flow of $144 million
  • Net cash provided by operating activities, six months ended June 30, 2026: $38 million
  • Free cash flow, six months ended June 30, 2026: $(129) million

Analysis

Second-quarter sales were $2,209 million, up 2.2% on a reported basis, while organic sales growth was 9.5%. The company attributed the organic result to strong performance across all reportable segments, driven primarily by volume and product mix. It also identified expected advance orders placed ahead of ERP cutovers as a contributor. Dental Solutions posted 15.2% organic growth, Infection Prevention and Surgical Solutions posted 10.1%, MedSurg posted 8.9%, Advanced Wound Care posted 7.1%, and Health Information Systems posted 5.4%.

Profitability showed a wide divergence between reported and adjusted results. GAAP operating income margin was 8.2%, down 170 bps, as net legal costs and separation and restructuring costs weighed on results. Adjusted operating income margin was 28.4%, up 650 bps, driven primarily by the IEEPA tariff refund and ERP-timing benefit. GAAP diluted earnings per share increased 3.9% to $0.53, while adjusted diluted earnings per share increased 50.9% to $2.55. GAAP SG&A increased 20.1% to $927 million, although adjusted SG&A as a percent of sales decreased 130 bps to 26.0%.

Cash flow improved in the quarter but remained weak over the first six months. Quarterly operating cash flow was $227 million and free cash flow was $144 million, with the company citing timing of tax payments and insurance proceeds. For the six months ended June 30, 2026, operating cash flow was $38 million and free cash flow was $(129) million. Six-month net sales declined 0.4% to $4,216 million on a reported basis, while organic growth was 5.8%; the sale of Purification and Filtration in September 2025 affected reported growth.

Management increased its full-year 2026 outlook for organic sales growth to +2.5% to +3.0%, adjusted diluted EPS to $7.10 to $7.20, and free cash flow to $200 million to $300 million. The organic growth outlook is +3.5% to +4.0% excluding approximately 100 bps of SKU exit impact. The company also announced its intent to separate Health Information Systems, which reported $354 million in second-quarter sales. The planned separation is positioned as part of portfolio optimization and a move toward a more focused, dedicated MedTech company.

Management, verbatim

The Solventum team delivered another quarter of strong execution with results ahead of our expectations while continuing to advance our transformation,

Bryan Hanson, chief executive officer of Solventum

We remain on track to achieve our long-term objectives as we build a more focused, dedicated MedTech company, well-positioned to create long-term shareholder value.

Bryan Hanson, chief executive officer of Solventum

Not in the filing

stated, not guessed
  • GAAP gross margin amount and percentage
  • Adjusted gross margin amount and percentage
  • GAAP operating income amount
  • Adjusted operating income amount
  • Cash balance
  • Debt balance
  • Capital-return amounts, including dividends and share repurchases
  • Prior-quarter comparisons for reported metrics
  • Full-year revenue guidance
  • Full-year gross-margin guidance
  • Full-year operating-expense guidance
  • Full-year tax-rate guidance
  • Prior outlook document for formal actual-versus-prior-guidance comparison

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about SOLV earnings dates

When is Solventum's next earnings date?
AlphAI has no date for SOLV yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.